Month: September 2026

• Event to be hosted on November 3, 2026 at 8:00 AM EST
• Featured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl

Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) —  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. The timing of the event has been shifted to better accommodate scheduling and the Company’s clinical development planning processes in ANCA-associated vasculitis (AAV).

Featuring leading experts in the fields of AAV and complement inhibition, the virtual event will provide an overview of the evolving treatment landscape and unmet need in AAV, and how izicopan’s differentiated chemistry, metabolic properties, and potential safety advantages could improve upon the existing standard of care in AAV.

The event will also provide updated thinking on InflaRx’s development strategy in AAV, including an overview of the anticipated clinical program. The event will feature presentations from members of InflaRx’s management team and invited external experts, followed by a question-and-answer session.

Featured key opinion leaders will include:

Peter A. Merkel, MD, MPH, Chief, Division of Rheumatology; Professor of Medicine (Rheumatology); Professor of Epidemiology in Biostatistics and Epidemiology; University of Pennsylvania, Philadelphia, PA USA

Prof. Dr. Jörg Köhl, Director of the Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany

The Capital Markets Event will take place on Tuesday, November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. To participate in the virtual event, participants are requested to pre-register here to receive an invite link and dial-in details to access the event. 

About the speakers

Peter A. Merkel, MD, MPH

Chief, Division of Rheumatology; Professor of Medicine (Rheumatology); Professor of Epidemiology in Biostatistics and Epidemiology; University of Pennsylvania, Philadelphia, PA, USA

Dr. Merkel is an internationally leading clinical and research expert in vasculitis, with particular expertise in the clinical investigation and treatment of AAV.

Dr. Merkel is the Chief of Rheumatology and a Professor of Medicine and Epidemiology at the University of Pennsylvania. Dr. Merkel is an internationally recognized researcher and clinical expert in vasculitis, scleroderma, and other systemic autoimmune diseases, and is an author on over 500 scientific publications. He is the Principal Investigator of the Vasculitis Clinical Research Consortium (VCRC) and the Vasculitis Patient-Powered Research Network (VPPRN), two leading international research infrastructures for clinical investigation in vasculitis, and is the co-Director of the newly established International Vasculitis Network (IVN). Dr. Merkel has led major clinical trials in AAV, including research on avacopan and other glucocorticoid-sparing treatment strategies. His research focuses on development of novel therapies for systemic autoimmune diseases, clinical trial design and conduct, outcome measure development, clinical epidemiology, genetic epidemiology, and biomarker discovery. Dr. Merkel received the 2023 Distinguished Clinical Scientist Award from the American College of Rheumatology.

Prof. Dr. Jörg Köhl

Director of the Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany

Dr. Köhl is a globally renowned translational complement scientist with a particular focus on the role of C5a/C5aR biology and its role in human disease.

He has over 35 years of medical and research experience and has published over 200 papers in the complement therapeutic landscape. His research has been continuously funded by the National Institutes of Health, the German Research Foundation, the Federal Ministry of Education and Research and the European Union since 1990. He has held several senior scientific positions, including a 20-year research appointment as Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center in the Divisions of Molecular Immunology and Immunobiology and his current position as the Founding Director of the Institute for Systemic Inflammation Research at the University of Lübeck, Germany. Dr. Köhl received his medical degree from the University of Mainz, Germany.

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7). In addition, InflaRx is planning for development of izicopan in ANCA-associated vasculitis and additional renal indications.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company, simplifying the process of trading and enhancing liquidity of the Company’s shares in the United States

Vancouver, BC, Sept. 21, 2026 (GLOBE NEWSWIRE) — SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company (“DTC”).

DTC is a subsidiary of The Depository Trust & Clearing Corporation (“DTCC”) and manages the electronic clearing and settlement of publicly traded securities in the United States. Securities eligible for electronic clearing and settlement through DTC are considered to be “DTC eligible” and may be traded through participating brokerage firms using electronic book-entry transfers, without the need for physical share certificates. DTC eligibility is expected to simplify the process of trading and enhance liquidity of the Company’s common shares in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers, reduces administrative cost, and enables the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

The Company’s common shares commenced trading on the OTCQB Venture Market under the symbol “SCTLF” on July 7, 2026, and continue to trade on the TSX Venture Exchange under “SCAI” and on the Frankfurt Stock Exchange under “MJ5”. DTC eligibility completes the operational groundwork behind the Company’s U.S. quotation, making it more straightforward for U.S. investors to hold and trade SalesCloser common shares through their existing brokerage relationships and making the Company’s shares more accessible to the U.S. investment community. Existing shareholders are not required to take any action as a result of the Company’s common shares becoming DTC eligible.

“Our shares have been quoted in the United States since July, and DTC eligibility is the step that makes holding them as routine as any other position in a U.S. brokerage account,” said Ali Tajskandar, Chief Executive Officer of SalesCloser. “As our commercial footprint expands across North America, we want the mechanics of owning the stock to be a non-issue for investors who want exposure to what we are building.”

About SalesCloser
SalesCloser.ai is a Vancouver-based AI software company focused on automating and scaling revenue generation through conversational AI. The Company’s platform enables businesses to deploy AI-powered virtual sales agents that engage prospects and customers across the sales lifecycle. SalesCloser’s agents conduct real-time, personalized interactions across voice, video, and digital channels, including lead qualification, product demonstrations, follow-ups, and meeting scheduling. By augmenting core sales functions, the platform helps organizations increase capacity, accelerate pipeline velocity, and improve conversion rates without a corresponding increase in headcount. The platform integrates with existing CRM and business systems, supports multilingual deployment, and delivers consistent, high-quality customer interactions across industries. SalesCloser operates under a subscription-based SaaS model, generating recurring revenue with strong visibility and high gross margins while continuously enhancing its AI capabilities. The Company’s technology is supported by a growing portfolio of patents and patent applications focused on improving the performance of AI-driven conversational workflows. SalesCloser.ai is listed on the TSX Venture Exchange under the ticker “SCAI”, on the OTCQB Venture Market under the ticker “SCTLF”, and on the Frankfurt Stock Exchange under the ticker “MJ5”. For more information, visit the SalesCloser investor site at: https://investors.salescloser.ai

Corporate Contact
Adrian Lim, CFO
Email: investors@salescloser.ai
Phone: 778 655 4329

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
SCAI@arxhq.com

Forward-Looking Statements
Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about and references to the anticipated benefits of DTC eligibility, including the simplification of the process of trading, enhanced liquidity of the Company’s common shares in the United States, accelerated settlement timelines, reduced administrative cost and friction for investors and broker-dealers, broader access to the Company’s common shares through U.S. brokerage firms, and greater accessibility of the Company’s shares to the U.S. investment community, the anticipated benefits of the Company’s quotation on the OTCQB Venture Market and its listings on the TSX Venture Exchange and the Frankfurt Stock Exchange, the Company’s plans to increase its visibility and accessibility within the United States capital markets, expected results from future operations, future growth of the Company’s products and platforms, the future development and increased use of products incorporating artificial intelligence, technology development initiatives, future profitability, business and acquisition strategies, opportunities, objectives, prospects, the impact of broader economic factors on the Company, and future events and performance. Sentences and phrases containing or modified by words such as “expect”, “anticipate”, “plan”, “continue”, “estimate”, “intend”, “may”, “will”, “project”, “predict”, “potential”, “targets”, “is designed to”, “strategy”, “should”, “believe”, “contemplate” and similar expressions, and the negative of such expressions, are not historical facts and are intended to identify forward-looking statements. Readers are cautioned to not place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and are based on, among other things, the expectations and analysis of current market trends and opportunities of management of the Company, such forward-looking statements have been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to, the Company’s continued ability to satisfy applicable DTC, OTCQB, TSX Venture Exchange and other regulatory requirements, the willingness of brokerage firms, custodians and institutional platforms to support trading in the Company’s common shares, market demand and investor interest, trading activity and liquidity in the Company’s common shares, changes to SalesCloser and other product’s revenue and profitability, changes to customer preferences, competition, use cases for SalesCloser and other products, economic uncertainty and instability as a result of the ongoing inflation and supply chain issues, higher interest rate climate, tightening of credit availability and recessionary risks, pandemic related risks, wars, tariffs, instability in global commodity and securities markets, shifts in consumer and institutional spending and marketing strategies, risks related to data breaches and privacy, the changing global market and competition for the products and services supplied by the Company, and the additional risk factors discussed in the continuous disclosure materials of the Company which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.